🚀 VC round data is live in beta, check it out!
Bio-Techne Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bio-Techne and similar public comparables like Bangkok Dusit Medical Services, Charles River, Qiagen, ALS and more.
Bio-Techne Overview
About Bio-Techne
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Founded
1976
HQ
Employees
3.1K
Website
Financials (LTM)
EV
$9B
Bio-Techne Financials
Bio-Techne reported last 12-month revenue of $1B and EBITDA of $435M.
In the same LTM period, Bio-Techne generated $842M in gross profit, $435M in EBITDA, and $311M in net income.
Revenue (LTM)
Bio-Techne P&L
In the most recent fiscal year, Bio-Techne reported revenue of $1B and EBITDA of $427M.
Bio-Techne expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $842M | XXX | $790M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $435M | XXX | $427M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 35% | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 31% | XXX | XXX | XXX |
| Net Profit | $311M | XXX | $306M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| Net Debt | — | — | $184M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bio-Techne Stock Performance
Bio-Techne has current market cap of $9B, and enterprise value of $9B.
Market Cap Evolution
Bio-Techne's stock price is $59.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $9B | 0.0% | XXX | XXX | XXX | $1.96 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBio-Techne Valuation Multiples
Bio-Techne trades at 7.7x EV/Revenue multiple, and 21.7x EV/EBITDA.
EV / Revenue (LTM)
Bio-Techne Financial Valuation Multiples
As of April 19, 2026, Bio-Techne has market cap of $9B and EV of $9B.
Equity research analysts estimate Bio-Techne's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bio-Techne has a P/E ratio of 29.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV/Revenue | 7.7x | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBITDA | 21.7x | XXX | 22.1x | XXX | XXX | XXX |
| EV/EBIT | 23.9x | XXX | 24.6x | XXX | XXX | XXX |
| EV/Gross Profit | 11.2x | XXX | 12.0x | XXX | XXX | XXX |
| P/E | 29.8x | XXX | 30.2x | XXX | XXX | XXX |
| EV/FCF | 37.2x | XXX | 36.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bio-Techne Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bio-Techne Margins & Growth Rates
Bio-Techne's revenue in the last 12 month grew by 5%.
Bio-Techne's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Bio-Techne's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bio-Techne's rule of X is 44% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Bio-Techne Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 44% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 34% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bio-Techne Public Comps
See public comps and valuation multiples for other Laboratory Services and Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bio-Techne | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| Charles River | XXX | XXX | XXX | XXX | XXX | XXX |
| Qiagen | XXX | XXX | XXX | XXX | XXX | XXX |
| ALS | XXX | XXX | XXX | XXX | XXX | XXX |
| Revvity | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bio-Techne M&A Activity
Bio-Techne acquired XXX companies to date.
Last acquisition by Bio-Techne was on XXXXXXXX, XXXXX. Bio-Techne acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bio-Techne
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBio-Techne Investment Activity
Bio-Techne invested in XXX companies to date.
Bio-Techne made its latest investment on XXXXXXXX, XXXXX. Bio-Techne invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bio-Techne
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bio-Techne
| When was Bio-Techne founded? | Bio-Techne was founded in 1976. |
| Where is Bio-Techne headquartered? | Bio-Techne is headquartered in United States. |
| How many employees does Bio-Techne have? | As of today, Bio-Techne has over 3K employees. |
| Who is the CEO of Bio-Techne? | Bio-Techne's CEO is Kim Kelderman. |
| Is Bio-Techne publicly listed? | Yes, Bio-Techne is a public company listed on Nasdaq. |
| What is the stock symbol of Bio-Techne? | Bio-Techne trades under TECH ticker. |
| When did Bio-Techne go public? | Bio-Techne went public in 1989. |
| Who are competitors of Bio-Techne? | Bio-Techne main competitors are Bangkok Dusit Medical Services, Charles River, Qiagen, ALS. |
| What is the current market cap of Bio-Techne? | Bio-Techne's current market cap is $9B. |
| What is the current revenue of Bio-Techne? | Bio-Techne's last 12 months revenue is $1B. |
| What is the current revenue growth of Bio-Techne? | Bio-Techne revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Bio-Techne? | Current revenue multiple of Bio-Techne is 7.7x. |
| Is Bio-Techne profitable? | Yes, Bio-Techne is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bio-Techne? | Bio-Techne's last 12 months EBITDA is $435M. |
| What is Bio-Techne's EBITDA margin? | Bio-Techne's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Bio-Techne? | Current EBITDA multiple of Bio-Techne is 21.7x. |
| What is the current FCF of Bio-Techne? | Bio-Techne's last 12 months FCF is $254M. |
| What is Bio-Techne's FCF margin? | Bio-Techne's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Bio-Techne? | Current FCF multiple of Bio-Techne is 37.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.